Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 15/20 | 0.80 |
| ▸ | MGLL | Q99685 | 2/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15020819 | 0.90 | HPGD (0.82) | HPGDMGLLHSD17B10ALDH1A1TSHR | |
| SCHEMBL23680788 | 0.89 | HPGD (1.00) | HPGDMGLLALDH1A1MEN1KMT2A | |
| SCHEMBL24463687 | 0.86 | HPGD (0.81) | HPGDMGLLHSD17B10ALDH1A1MEN1 | |
| SCHEMBL698814 | 0.83 | MGLL (0.64) | HPGDMGLLHSD17B10ALDH1A1MEN1 | |
| SCHEMBL4343393 | 0.83 | HPGD (0.58) | HPGDMGLLALDH1A1NPC1GLA | |
| SCHEMBL120600 | 0.82 | HSD17B10 (1.00) | HPGDMGLLHSD17B10ALDH1A1MEN1 | |
| SCHEMBL29784251 | 0.82 | HSD17B10 (1.00) | HPGDMGLLHSD17B10ALDH1A1MEN1 | |
| SCHEMBL3065613 | 0.81 | HSD17B10 (0.82) | HPGDMGLLHSD17B10ALDH1A1MEN1 | |
| SCHEMBL2285726 | 0.79 | MGLL (0.61) | HPGDMGLLHSD17B10ALDH1A1MEN1 | |
| SCHEMBL20897871 | 0.79 | MGLL (1.00) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809541-B2 | Heterocyclic compound, and composition for treating inflammatory diseases using same | NEOPHARM CO., LTD. (KR) | 2014-08-19 | — | — | US | disclosed |
| US-8809541-B2 | Heterocyclic compound, and composition for treating inflammatory diseases using same | NEOPHARM CO., LTD. (KR) | 2014-08-19 | — | — | US | disclosed |
| US-20130158047-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | NEOPHARM CO., LTD. (KR) | 2013-06-20 | — | — | US | disclosed |
| US-20130158047-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | NEOPHARM CO., LTD. (KR) | 2013-06-20 | — | — | US | disclosed |
| WO-2012026766-A2 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | (주)네오팜 (KR) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158047-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | F2RL1, F2R, F2RL3 | HPGD 399/4885MGLL 1982/4885HSD17B10 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.